FDA Hearing Weighs Psychedelic Therapies and Safety Protocols

The FDA convened a public hearing to gather input on psychedelic treatments for conditions like depression and PTSD. While many speakers endorsed the therapies, others called for standardized trials and risk mitigation measures. The agency also highlighted recent steps to accelerate research, including priority review vouchers for psilocybin studies.

The hearing drew 80 speakers representing veterans groups, industry leaders, and clinical researchers. FDA officials framed the session within a broader federal initiative, citing an April executive order that established a policy of accelerating research models and drug approvals for psychedelics. The agency has already taken concrete steps, including awarding priority review vouchers to companies studying psilocybin for depression and methylone for PTSD, and permitting an early-phase trial of noribogaine for alcohol use disorder.

A central challenge discussed was maintaining double-blind conditions in psychedelic trials, since participants often discern whether they received an active substance. FDA authors in a New England Journal of Medicine commentary noted this can create a "disappointment effect" among those who believe they received a placebo. Speakers urged flexibility in trial design while still calling for standardized endpoints and risk mitigation strategies.